Recombinant Staphylococcus aureus Isoleucine--tRNA ligase (ileS), partial

What is Isoleucyl-tRNA synthetase (IleRS) and what is its primary function in S. aureus?

Isoleucyl-tRNA synthetase (IleRS) is an essential aminoacyl-tRNA synthetase responsible for decoding isoleucine codons in all domains of life, including Staphylococcus aureus. The primary function of IleRS is to catalyze the attachment of isoleucine to its cognate tRNA (tRNA^Ile), producing isoleucyl-tRNA^Ile, which is crucial for protein synthesis. S. aureus IleRS, like other bacterial IleRS enzymes, has a class I aminoacyl-tRNA synthetase structure built around a conserved N-terminal Rossmann fold catalytic domain that encloses the synthetic site. This enzyme plays a vital role in bacterial protein synthesis by ensuring the accurate incorporation of isoleucine into growing polypeptide chains .

How does the structure of S. aureus IleRS compare to IleRS from other organisms?

• The enzyme contains a connective peptide 1 (CP1) inserted between the two halves of the catalytic domain, which folds into an independent domain hosting the post-transfer editing site .

• Unlike some IleRS enzymes (such as from E. coli), S. aureus IleRS appears to share structural similarities with other mupirocin-susceptible IleRS enzymes, particularly in regions associated with the Rossmann fold .

• Specific amino acid positions in S. aureus IleRS are susceptible to mutations that confer resistance to mupirocin, including positions 213 (Asn→Asp), 588 (Val→Phe), 631 (Val→Phe), and 804 (Leu→Phe) relative to the published S. aureus ileS gene sequence .

These structural characteristics make S. aureus IleRS an important target for antibiotics and influence its specificity and editing capabilities.

What are the editing mechanisms in S. aureus IleRS and how do they ensure translational fidelity?

S. aureus IleRS, like other IleRS enzymes, employs editing mechanisms to ensure translational fidelity, though with notable species-specific variations:

IleRS editing occurs through two main pathways:

• Post-transfer editing: This is the dominant proofreading mechanism where misaminoacylated tRNAs are hydrolyzed in a separate well-defined domain. In this pathway, the aminoacylated 3′-end of the tRNA translocates from the synthetic site to the distant editing site (CP1 domain), positioning the amino acid for proofreading .

• Pre-transfer editing: While some organisms (like E. coli) show tRNA-dependent pre-transfer editing where non-cognate aa-AMP is hydrolyzed in the synthetic site, this mechanism appears to be optional in some IleRS enzymes and its prevalence in S. aureus IleRS specifically is not thoroughly characterized based on the provided search results .

These editing mechanisms are crucial because IleRS can activate non-cognate valine with a relatively low discrimination factor of approximately 200, necessitating robust editing to prevent misincorporation of valine at isoleucine codons . The conserved post-transfer editing domain appears to be the main checkpoint in ensuring accurate aminoacylation.

How does S. aureus IleRS discriminate between isoleucine and structurally similar amino acids?

S. aureus IleRS discriminates between isoleucine and structurally similar amino acids (particularly valine) through a combination of mechanisms:

• Initial substrate selection: The synthetic site provides initial discrimination between isoleucine and other amino acids, though this discrimination is relatively weak for valine (discrimination factor of approximately 200) .

• Post-transfer editing: The primary discrimination mechanism involves the CP1 domain, which contains the post-transfer editing site that hydrolyzes misaminoacylated tRNA^Ile containing non-cognate amino acids like valine .

• Conformational changes: Based on studies of IleRS enzymes, fluorescence changes observed during substrate binding suggest that conformational adjustments in the enzyme contribute to substrate discrimination. Experiments using tryptophan fluorescence have revealed that different ligands (including substrates and inhibitors) induce distinct conformational states in the enzyme, which likely play a role in discrimination .

This multi-layered discrimination process is essential for maintaining translational accuracy and preventing the misincorporation of valine at isoleucine codons, which could lead to misfolded or dysfunctional proteins.

What mutations in the S. aureus ileS gene confer resistance to mupirocin, and how do they affect enzyme function?

Several specific mutations in the S. aureus ileS gene have been identified that confer low-level resistance to mupirocin (LLR-Mup). Based on the analysis of clinical isolates and laboratory-induced resistant strains, the following mutations have been documented:

The G1762T mutation appears particularly significant as it was the only mutation detected in a laboratory-derived resistant strain (SA-7R) that was not present in its mupirocin-susceptible parent strain (SA-7S) . This mutation affects the Rossmann fold of IleRS, which is critical for its enzymatic function.

These mutations likely alter the binding affinity of mupirocin to the enzyme's active site without significantly compromising its ability to recognize and activate isoleucine. The preservation of enzymatic function with reduced inhibitor binding explains the low-level resistance phenotype .

How does mupirocin inhibit S. aureus IleRS and what is the biochemical basis for this interaction?

Mupirocin (pseudomonic acid, PS-A) inhibits S. aureus IleRS through a complex mechanism:

• Competitive binding: Mupirocin acts as a competitive inhibitor that selectively targets bacterial IleRS by binding to the synthetic site, preventing isoleucine activation .

• Slow-tight binding mechanism: Recombinant S. aureus IleRS is inhibited by mupirocin via a slow-tight binding competitive mechanism. Initially, mupirocin forms an E·J complex with the enzyme (where J represents mupirocin) with a Kj of approximately 2 nM. This complex then undergoes isomerization to form a stabilized E*·J complex with a significantly stronger binding affinity (K*j = 50 pM) .

• Structural mimicry: Mupirocin structurally resembles isoleucyl-AMP (the intermediate in the aminoacylation reaction), allowing it to occupy the synthetic site of IleRS .

The binding of mupirocin to IleRS leads to the accumulation of uncharged isoleucyl-tRNA, which triggers the synthesis of the alarmone (p)ppGpp. This molecule induces the stringent response, a global transcriptional and translational control mechanism that allows bacteria to adapt to nutritional deprivation . The strength of this interaction is reflected in the experimental determination that binding occurs with 1:1 stoichiometry and induces measurable changes in the enzyme's tryptophan fluorescence .

What are the optimal conditions for expressing and purifying recombinant S. aureus IleRS for experimental studies?

While the search results do not provide a complete protocol for expressing and purifying recombinant S. aureus IleRS, we can infer recommended conditions from the methodologies described:

For optimal expression and purification of recombinant S. aureus IleRS:

• Expression system: A bacterial expression system (typically E. coli) with an appropriate vector containing the full-length or partial S. aureus ileS gene is commonly used .

• Culture conditions: Based on studies with other IleRS enzymes, growth at 30-37°C in rich media (such as LB or similar) supplemented with appropriate antibiotics for plasmid selection is recommended .

• Purification approach:

  • Initial capture using affinity chromatography (His-tag or other suitable affinity tag)

  • Ion exchange chromatography for further purification

  • Size exclusion chromatography as a polishing step

• Buffer conditions: For enzyme activity studies, buffers containing components such as 50 mM HEPES (pH 7.5), 10 mM MgCl₂, 5 mM DTT, and 0.1 μg/μl BSA have been successfully used .

• Storage conditions: The purified enzyme should be stored with glycerol (typically 20-50%) at -80°C to maintain activity.

Proper validation of the recombinant enzyme should include activity assays measuring aminoacylation of tRNA^Ile, inhibition studies with known inhibitors like mupirocin, and verification of protein purity by SDS-PAGE and/or mass spectrometry .

What methods are most effective for studying the interaction between S. aureus IleRS and its inhibitors?

Several effective methods have been documented for studying interactions between S. aureus IleRS and its inhibitors:

• Enzyme kinetics studies:

  • Transient and steady-state kinetic analyses to characterize inhibition mechanisms

  • Determination of inhibition constants (Ki) for competitive inhibitors

  • Slow-tight binding kinetics analysis for inhibitors like mupirocin

• Binding studies using fluorescence spectroscopy:

  • Monitoring changes in enzyme tryptophan fluorescence upon inhibitor binding

  • Using fluorescence to detect conformational changes in the enzyme

  • Energy transfer experiments with fluorescent inhibitor analogues (e.g., SB-205952, which produces a 37% quenching of IleRS fluorescence)

• Radioligand binding assays:

  • Using [³H]-labeled inhibitors (e.g., [³H]PS-A) to confirm binding stoichiometry

  • Competition assays to determine relative binding affinities

• PPi/ATP exchange assays:

  • Particularly useful for overcoming tight-binding artifacts when studying inhibitors with very high affinity (K*j << [E])

• Inhibitor reversal rate measurements:

  • Measuring relaxation between spectroscopically different complexes to determine dissociation rates

These methods provide complementary information about inhibitor binding mechanisms, affinities, and kinetics, offering a comprehensive characterization of IleRS-inhibitor interactions.

How can researchers accurately identify and characterize mutations in the ileS gene from clinical S. aureus isolates?

To accurately identify and characterize mutations in the ileS gene from clinical S. aureus isolates, researchers should follow this methodological approach:

• Sample preparation:

  • Isolate genomic DNA from S. aureus clinical strains using standardized extraction methods such as those described by Cookson et al.

  • Include appropriate control strains with known ileS sequences for comparison

• PCR amplification:

  • Design primers flanking the entire coding sequence of the ileS gene. Primers such as IleS-1 (5′-TACCGCGAGCAATCGTCCCT-3′) and IleS-2 (5′-TGTTGGCATCGTGGGCATAG-3′) have been successfully used

  • Optimize PCR conditions for high-fidelity amplification of the approximately 3 kb ileS gene

• Sequencing and analysis:

  • Perform full-length sequencing using methods such as the BigDye terminator cycle sequencing method

  • Use multiple overlapping reads to ensure accurate sequence determination

  • Compare sequences with reference S. aureus ileS gene sequences (e.g., GenBank accession no. X74219)

• Mutation identification and validation:

  • Analyze sequences for single nucleotide polymorphisms (SNPs) associated with mupirocin resistance

  • Pay special attention to known mutation hotspots: positions 637 (A→G), 1762 (G→T), 1891 (G→T), and 2412 (A→T)

  • Confirm the presence of mutations by repeated sequencing or alternative methods such as SNP-specific PCR

• Phenotypic correlation:

  • Determine the mupirocin MIC for each isolate using standardized methods such as E-test

  • Correlate identified mutations with resistance phenotypes to establish genotype-phenotype relationships

This comprehensive approach enables accurate identification of ileS mutations and provides insight into the molecular basis of mupirocin resistance in clinical S. aureus isolates.

What global cellular changes occur in S. aureus in response to mupirocin treatment?

Mupirocin treatment triggers a comprehensive cellular response in S. aureus, characterized by significant shifts in gene expression and metabolism:

• Induction of the stringent response:

  • Mupirocin inhibition of IleRS leads to accumulation of uncharged tRNA^Ile

  • This triggers synthesis of the alarmone (p)ppGpp

  • (p)ppGpp activates the stringent response, a global adaptation mechanism

• Transcriptional reprogramming:

  • Downregulated processes:

    • Nucleotide biosynthesis

    • DNA metabolism

    • Energy metabolism

    • Translation

  • Upregulated processes:

    • Expression of isoleucyl-tRNA synthetase (ileS)

    • Branched-chain amino acid pathway

    • Oxidative stress resistance genes (ahpC and katA)

    • Stress protection genes (yvyD homologue SACOL0815, SACOL1759, and SACOL2131)

    • Transport processes

• Activation of virulence regulators:

  • Induced transcription of multiple virulence-associated regulators:

    • arlRS

    • saeRS

    • sarA

    • sarR

    • sarS

    • sigB

• Regulatory networks involved:

  • The response appears to involve the global regulators CodY and SigB, which help shape the adaptation to mupirocin exposure

These global changes reflect a coordinated bacterial survival strategy in response to the translational stress imposed by mupirocin. The upregulation of stress resistance genes and virulence regulators suggests that mupirocin treatment, while inhibiting bacterial growth, may also trigger adaptive responses that could influence pathogenesis and survival in certain contexts.

How can recombinant S. aureus IleRS be used to screen for novel antimicrobial compounds?

Recombinant S. aureus IleRS provides an excellent platform for screening novel antimicrobial compounds through the following methodological approaches:

• High-throughput enzymatic assays:

  • ATP-PPi exchange assays to measure inhibition of amino acid activation

  • Aminoacylation assays using purified tRNA^Ile to assess the complete enzymatic reaction

  • Fluorescence-based assays monitoring changes in enzyme tryptophan fluorescence upon inhibitor binding

• Structure-guided screening strategies:

  • Virtual screening against the IleRS active site based on crystal structures

  • Fragment-based approaches targeting specific pockets in the enzyme

  • Design of analogues based on known inhibitors such as mupirocin and non-hydrolyzable analogues of isoleucyl-AMP (e.g., Ile-ol-AMP and Ile-NHSO2-AMP)

• Differential screening against IleRS from various species:

  • Parallel screening against human and bacterial IleRS to identify compounds with selective activity

  • Testing against mupirocin-resistant IleRS variants to discover compounds that retain activity against resistant enzymes

• Validation of leads:

  • Determination of inhibition mechanisms (competitive, non-competitive, slow-binding) using transient and steady-state techniques

  • Measurement of binding constants and stoichiometry

  • Assessment of reversibility through kinetic studies

• Secondary cellular assays:

  • Growth inhibition assays using wild-type and mupirocin-resistant S. aureus strains

  • Transcriptomic analysis to confirm target engagement by monitoring stringent response activation

This comprehensive approach leverages the detailed biochemical understanding of S. aureus IleRS to identify compounds with novel mechanisms of action or improved properties compared to existing inhibitors like mupirocin.

What approaches can be used to investigate the role of IleRS in the S. aureus stringent response and stress adaptation?

To investigate the role of IleRS in the S. aureus stringent response and stress adaptation, researchers can employ several sophisticated approaches:

• Genetic manipulation strategies:

  • Construction of conditional ileS mutants using inducible promoters

  • Site-directed mutagenesis to create variants with altered catalytic efficiency or editing capabilities

  • Introduction of specific resistance mutations to assess their impact on stringent response activation

• Comprehensive transcriptomic profiling:

  • RNA-seq or DNA microarray analysis comparing wild-type and ileS-mutant strains under various stress conditions

  • Time-course experiments following mupirocin treatment to track the temporal progression of the stringent response

  • Correlation of transcriptomic changes with (p)ppGpp levels

• Proteomics approaches:

  • 2-dimensional gel electrophoresis combined with mass spectrometry to identify proteins with altered synthesis patterns

  • Quantitative proteomics (e.g., SILAC, iTRAQ) to measure protein abundance changes

  • Phosphoproteomics to identify signaling events in the stringent response pathway

• Metabolomic analysis:

  • Targeted metabolomics focusing on amino acids, particularly branched-chain amino acids

  • Measurement of (p)ppGpp and other alarmone levels

  • Global metabolic profiling to identify metabolic pathway adjustments

• Integration with virulence regulation:

  • Investigation of the relationship between IleRS inhibition and the activation of virulence-associated regulators (arlRS, saeRS, sarA, sarR, sarS, and sigB)

  • Assessment of virulence factor production under conditions of IleRS inhibition

  • In vivo models to determine the impact of the stringent response on pathogenesis

These integrated approaches would provide a comprehensive understanding of how IleRS functions not only as an essential enzyme for protein synthesis but also as a sensor for amino acid availability and a trigger for adaptive responses in S. aureus.

What are the common challenges in analyzing IleRS activity data and how can they be addressed?

Researchers commonly encounter several challenges when analyzing IleRS activity data, particularly in the context of inhibition studies and resistance mechanisms:

• Tight-binding inhibitor artifacts:

  • Challenge: When studying high-affinity inhibitors like mupirocin (K*j = 50 pM), conventional enzyme kinetics approaches fail when inhibitor dissociation constants are much lower than enzyme concentration ([E]) .

  • Solution: Use PPi/ATP exchange assays with substrate concentrations much higher than Km, thus raising the apparent inhibition constant (K*j,app) well above the enzyme concentration .

• Multiple editing pathways:

  • Challenge: Distinguishing between pre-transfer and post-transfer editing activities in IleRS enzymes.

  • Solution: Design specialized assays that selectively measure each pathway, such as thin-layer chromatography to detect released amino acids or misaminoacylated tRNA species .

• Background tRNA aminoacylation:

  • Challenge: When using partially purified tRNA preparations, background aminoacylation by contaminating tRNAs can confound results.

  • Solution: Use highly purified tRNA^Ile preparations (>85% acceptor activity) obtained through selective hybridization methods followed by reverse phase chromatography when necessary .

• Slow enzyme kinetics:

  • Challenge: Some IleRS reactions, particularly with non-cognate substrates, proceed slowly and can lead to low plateau levels of aminoacylated tRNA.

  • Solution: Include EF-Tu in reaction mixtures to prevent accumulation at low plateau levels by sequestering aminoacylated tRNA as it forms .

• Conformational heterogeneity:

  • Challenge: IleRS undergoes conformational changes during catalysis and inhibitor binding, complicating kinetic analysis.

  • Solution: Use spectroscopic techniques such as tryptophan fluorescence to monitor conformational states and implement transient kinetic competition experiments to characterize different enzyme-ligand complexes .

Addressing these challenges requires careful experimental design and the integration of multiple complementary techniques to generate reliable and interpretable data.

How can researchers differentiate between different mechanisms of mupirocin resistance in S. aureus isolates?

Differentiating between various mechanisms of mupirocin resistance in S. aureus isolates requires a multi-faceted approach that integrates genetic, biochemical, and phenotypic analyses:

• Phenotypic characterization:

  • MIC determination: Low-level resistance (MIC 8-256 μg/ml) typically indicates chromosomal ileS mutations, while high-level resistance (MIC >512 μg/ml) suggests the presence of acquired resistance genes .

  • Growth kinetics: Measure growth rates in the presence of various mupirocin concentrations to assess the degree of resistance.

• Genetic analysis:

  • Sequencing of chromosomal ileS: Full-length sequencing to identify specific mutations associated with low-level resistance (A637G, G1762T, G1891T, A2412T) .

  • PCR screening for mupA/ileS2: Detection of the plasmid-borne mupA (also known as ileS2) gene associated with high-level resistance.

  • Whole genome sequencing: To identify novel or multiple mutations that might contribute to resistance.

• Biochemical characterization:

  • Enzyme kinetics: Purify IleRS from resistant isolates and determine inhibition constants (Ki) for mupirocin.

  • Binding assays: Use [³H]PS-A or fluorescence-based assays to measure mupirocin binding affinities to wild-type and mutant IleRS enzymes .

• Evolutionary analysis:

  • Serial passage experiments: Perform controlled evolution experiments with increasing mupirocin concentrations to identify the stepwise accumulation of resistance mutations .

  • Competition assays: Assess the fitness costs associated with different resistance mechanisms.

• Expression analysis:

  • qRT-PCR: Measure expression levels of ileS and potential efflux pumps that might contribute to resistance.

  • Proteomics: Quantify IleRS protein levels in resistant versus susceptible strains.

By systematically applying these approaches, researchers can comprehensively characterize the resistance mechanisms in clinical isolates, distinguish between chromosomal mutations and acquired resistance genes, and potentially identify novel resistance determinants or combinations of mechanisms that contribute to the observed phenotype.

What are the promising areas for future research on S. aureus IleRS structure-function relationships?

Several promising areas for future research on S. aureus IleRS structure-function relationships warrant investigation:

• Structural basis of mupirocin resistance:

  • Solving crystal structures of wild-type and mutant S. aureus IleRS in complex with mupirocin

  • Computational modeling of how specific mutations (A637G, G1762T, G1891T, A2412T) alter mupirocin binding while preserving enzymatic function

  • Structure-based design of next-generation inhibitors that maintain activity against resistant variants

• Editing mechanisms exploration:

  • Detailed characterization of pre-transfer and post-transfer editing in S. aureus IleRS

  • Investigation of whether S. aureus IleRS possesses tRNA-dependent pre-transfer editing, which has been characterized in E. coli IleRS

  • Structure-function analysis of the CP1 domain and its role in maintaining translational fidelity

• Allostery and conformational dynamics:

  • Time-resolved studies of conformational changes during the catalytic cycle

  • Investigation of allosteric communication between the synthetic site and editing domain

  • Single-molecule studies to capture transient states during aminoacylation and editing

• Interface with translation machinery:

  • Structural and functional studies of the interaction between S. aureus IleRS and elongation factors

  • Investigation of potential species-specific differences in these interactions

  • Exploration of how IleRS contributes to translational control during stress conditions

• Novel inhibitory strategies:

  • Development of inhibitors targeting the editing site rather than the synthetic site

  • Exploration of allosteric inhibitors that disrupt communication between domains

  • Design of dual-target inhibitors that simultaneously affect IleRS and other components of the translation machinery

These research directions could significantly advance our understanding of S. aureus IleRS and potentially lead to novel therapeutic strategies to combat mupirocin-resistant S. aureus infections.

How might advanced techniques in structural biology and biochemistry reveal new insights about S. aureus IleRS function and inhibition?

Advanced techniques in structural biology and biochemistry offer powerful approaches to uncover new insights about S. aureus IleRS function and inhibition:

• Cryo-electron microscopy (Cryo-EM):

  • Visualization of IleRS in complex with tRNA^Ile, revealing conformational changes during the aminoacylation process

  • Structural determination of IleRS as part of larger macromolecular complexes involving translation machinery

  • Capturing dynamic states that may be difficult to crystallize

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS):

  • Mapping conformational changes induced by substrate binding or inhibitor interactions

  • Identifying flexible regions critical for enzyme function

  • Characterizing allosteric networks within the protein

• Single-molecule techniques:

  • FRET-based approaches to monitor real-time conformational changes during catalysis

  • Optical tweezers to measure forces involved in tRNA binding and translocation

  • Direct observation of editing pathway selection at the single-molecule level

• Time-resolved crystallography and spectroscopy:

  • Capturing intermediate states in the catalytic cycle

  • Monitoring structural transitions during amino acid activation and transfer

  • Understanding the timing of conformational changes relative to chemical steps

• Integrative structural biology approaches:

  • Combining multiple structural techniques (X-ray crystallography, NMR, SAXS, Cryo-EM)

  • Computational modeling and molecular dynamics simulations to fill gaps in experimental data

  • Cross-linking mass spectrometry to identify interacting surfaces

• Precision enzymology:

  • Pre-steady-state kinetics to resolve individual steps in the catalytic mechanism

  • Isotope effects to probe transition states

  • Site-specific incorporation of non-canonical amino acids or spectroscopic probes at key positions

These cutting-edge approaches would provide unprecedented insights into the molecular mechanisms of S. aureus IleRS function, offering new perspectives on how to target this enzyme for antimicrobial development and overcome resistance mechanisms through rational drug design.

How does S. aureus IleRS differ evolutionarily from IleRS in other bacterial species and eukaryotes?

The evolutionary relationships and differences between S. aureus IleRS and its counterparts in other species reveal important insights about functional specialization and potential drug targets:

• Sequence conservation and divergence:

  • While the catalytic core and active site residues are highly conserved across bacterial IleRS enzymes, significant differences exist in regions associated with tRNA recognition and editing functions .

  • S. aureus IleRS shares higher sequence similarity with other Gram-positive bacterial IleRS enzymes than with those from Gram-negative bacteria or eukaryotes.

  • Key differences between bacterial and eukaryotic IleRS enzymes, particularly in the Rossmann fold region, explain the selective toxicity of mupirocin toward bacterial enzymes .

• Editing mechanisms:

  • Unlike E. coli IleRS, which demonstrates robust tRNA-dependent pre-transfer editing activity, the prevalence and importance of this editing pathway in S. aureus IleRS remains less characterized .

  • The post-transfer editing domain (CP1) shows significant conservation across species, reflecting its crucial role in maintaining translational fidelity .

• Inhibitor sensitivity:

  • S. aureus IleRS exhibits high sensitivity to mupirocin (with Ki values in the nanomolar range) , while eukaryotic IleRS enzymes are significantly less affected.

  • Specific mutations in S. aureus IleRS (like G1762T affecting the Rossmann fold) can reduce mupirocin sensitivity while maintaining catalytic function, highlighting the evolutionary plasticity of this enzyme .

• Domain architecture:

  • Although the fundamental domain architecture is conserved across species, subtle differences in interdomain communications and interactions with tRNA likely contribute to species-specific functional characteristics.

  • These architectural differences may influence the specificity of inhibitors and the mechanisms of resistance that can emerge.

Understanding these evolutionary relationships provides crucial context for interpreting resistance mutations and developing antimicrobials with improved specificity profiles.

How do resistance mechanisms in S. aureus IleRS compare to other antibiotic resistance mechanisms in S. aureus?

Resistance mechanisms involving S. aureus IleRS demonstrate both unique features and parallels to other antibiotic resistance mechanisms in this pathogen:

• Point mutations vs. acquired resistance genes:

  • IleRS resistance pattern: Low-level mupirocin resistance typically arises from point mutations in the chromosomal ileS gene (e.g., A637G, G1762T), while high-level resistance usually involves acquisition of the plasmid-borne mupA/ileS2 gene .

  • Comparison: This pattern parallels other antibiotic resistance mechanisms in S. aureus, such as:

    • β-lactam resistance: Point mutations in penicillin-binding proteins conferring low-level resistance vs. acquisition of mecA for high-level resistance

    • Fluoroquinolone resistance: Chromosomal mutations in gyrA/gyrB vs. acquisition of qnr genes

• Target site modifications:

  • IleRS mechanism: Mutations affecting the Rossmann fold (G1762T) alter the binding site for mupirocin while preserving enzymatic function .

  • Comparison: Similar target modification strategies are seen with:

    • Linezolid resistance via mutations in 23S rRNA

    • Daptomycin resistance through alterations in membrane composition

• Mutation frequency and development:

  • IleRS pattern: Mupirocin resistance can be laboratory-induced through serial passage, suggesting a stepwise acquisition of mutations .

  • Comparison: This gradual development of resistance resembles:

    • Vancomycin resistance development through cell wall thickening

    • Daptomycin resistance emergence through cumulative mutations

• Fitness costs:

  • IleRS implications: The preservation of IleRS function despite mutations suggests minimal fitness costs, explaining the persistence of resistant strains.

  • Comparison: Variable fitness costs are associated with different resistance mechanisms in S. aureus, with some (like certain mecA variants) imposing significant metabolic burdens while others have minimal impact.

• Global regulatory responses:

  • IleRS-related response: Mupirocin inhibition of IleRS triggers the stringent response, affecting multiple virulence regulators (arlRS, saeRS, sarA, etc.) .

  • Comparison: This global response parallels how other antibiotics (like linezolid or oxazolidinones) can trigger stress responses that affect virulence gene expression.